Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Increases IPO Target to $221M

NEW YORK – Sophia Genetics has priced its initial public offering of 13 million common shares at $17 to $19 per share, for anticipated gross proceeds of $221 million to $247 million before underwriting discounts, commissions, and other expenses. The firm expects to hold its IPO July 23.

The bioinformatics company, with twin headquarters in Saint-Sulpice, Switzerland, and in Boston, disclosed its IPO price range in an amended registration statement filed Monday with the US Securities and Exchange Commission. Sophia said earlier this month that its IPO would raise no more than $100 million.

In the filing, Sophia said that Instrumentarium Holdings would purchase $20 million common shares in a private placement at the same per-share price as the IPO.

As previously announced, the shares will trade on the Nasdaq Global Select Market under the ticker symbol SOPH. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse are serving as joint bookrunning managers for the offering.

Sophia has raised at least $251 million in private equity, most recently in a $110 million Series F round that closed in October. The Swiss-American company offers a core genomic analytics platform called Data Driven Medicine, or DDM, to support all of its analytics pipelines and builds components including artificial intelligence technology for predicting variant pathogenicity.

In its SEC filing, the firm reported nearly $9 million in revenues during the first quarter of 2021. That is 20 percent higher than the $7.5 million booked in the same period a year earlier.

Sophia had a net loss of close to $12.7 million in Q1, compared to a loss of $10.5 million in the year-earlier quarter.

As of March 31, the company had $57.1 million in cash and equivalents.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.